drugset
drugset / Trial / NCT00648167

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

NCT00648167 ↗

Phase 2 Completed 55 enrolled Keryx Biopharmaceuticals Collaborative Study Group (CSG) · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease.

Timeline

Start
2008-03
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric Citrate Unknown 12 g —

Indications

end stage renal failure hyperphosphatemia